Medicare Advantage Continues To Grow Despite Health Insurer Exits

Why It Matters

The shift in market share underscores growing competition and cost pressures in the MA space, directly influencing insurer profitability and Medicare policy direction.

Key Takeaways

• Medicare Advantage enrollment at 55% of eligible beneficiaries in 2026.
• UnitedHealth's market share fell to 26%, losing 647k enrollees.
• Humana added 1.3 million enrollees, now holds 20% market share.
• Enrollment growth slowed as insurers retreat from unprofitable markets.
• Analysts cite easing cost trends, supporting health‑insurer earnings outlook.

Pulse Analysis

Medicare Advantage remains the dominant vehicle for senior health coverage, now serving more than half of eligible beneficiaries. The program’s appeal lies in its supplemental benefits—ranging from prescription drug coverage to dental and vision—that traditional Medicare lacks. As the baby‑boomer cohort ages, demand for integrated, value‑added plans sustains enrollment, even as the overall growth rate eases. Policymakers watch these trends closely, given MA’s impact on federal spending and the broader health‑care ecosystem.

The competitive landscape is reshaping, with UnitedHealth Group’s share slipping to 26% after a loss of nearly 647,000 members, while Humana’s aggressive expansion added 1.3 million new enrollees, lifting its share to 20%. This realignment reflects strategic retreats by major carriers from markets where provider networks are thin or costs are high. Smaller regional insurers are poised to capture displaced members, intensifying price competition and potentially driving innovation in care coordination and telehealth services.

Financial markets have responded positively to signs that Medicare Advantage cost growth is moderating. Humana reaffirmed its 2026 EPS guidance of at least $9, and shares of UnitedHealth and CVS Health rallied on analyst optimism about easing utilization trends. Investors are betting that insurers can balance richer benefit packages with disciplined cost management, a balance that will shape future earnings and could influence legislative discussions on MA reimbursement rates.